

Emetic Risk of Single Intravenous Agents in Adults

This table is a list of IV agents in the CCO Drug Formulary and their emetogenic classification.

Drug Name	Emetic Risk Category
Aflibercept*	Low
Aldesleukin*	Moderate: IV doses >12-15 MU /m ² Low: IV doses ≤ 12 MU /m ² Minimal: Intralesional
Alemtuzumab	Minimal
Amsacrine	Low
Arsenic Trioxide	Moderate
L-Asparaginase	Minimal
Atezolizumab	Low
Avelumab	Minimal
Azacitidine	Moderate
Bendamustine	Moderate
Bevacizumab	Minimal
Bleomycin	Minimal
Blinatumomab	Low
Bortezomib	Low
Brentuximab vedotin	Low
Cabazitaxel	Low
Carboplatin*	Moderate + NK1 antagonist: AUC ≥ 5 Moderate: AUC < 5
Carfilzomib	Low
Carmustine	High: > 250 mg /m ² Moderate: ≤ 250 mg /m ²
Cetuximab	Minimal
Cisplatin	High: ≥ 70 mg /m ² Moderate: < 70 mg /m ²
Cladribine	Minimal
Cyclophosphamide	High: > 1500 mg /m ² Moderate: ≤ 1500 mg /m ²
Cytarabine	Moderate: > 200 mg /m ² Low: ≤ 200 mg /m ²
Dacarbazine*	Moderate
Dactinomycin*	Moderate
Daratumumab*	Minimal

The agents listed in this table are based on the CCO Drug Formulary as at February 2019, and may not be inclusive of all agents. Refer to the Drug Formulary website for the most up-to-date information on individual agents, to find the latest CCO Antiemetic Recommendations, and for more information on emetic risk of multi-drug combinations. The contents of this document are not a substitute for the advice of a qualified health professional. Any person consulting it is expected to use independent qualified clinical judgment and skills, or seek out the advice of a qualified health professional before applying any information contained herein. Cancer Care Ontario does not make any representation or warranty as to the accuracy, reliability, completeness or fitness for a particular purpose of the information in this document, and disclaims all liability for the use of this document, and for any claims, actions, demands or suits that arise from such use.

Drug Name	Emetic Risk Category
Daunorubicin	Moderate
Dexrazoxane	Minimal
Docetaxel	Low
Decitabine*	Minimal
Doxorubicin*	High: $\geq 60 \text{ mg/m}^2$ Moderate: $< 60 \text{ mg/m}^2$
Doxorubicin Liposomal (pegylated)	Low
Durvalumab	Minimal
Epirubicin	High: $> 90 \text{ mg/m}^2$ Moderate: $\leq 90 \text{ mg/m}^2$
Eribulin	Low
Erwinia L-asparaginase	Minimal
Etoposide	Low
Fludarabine	Minimal
Fluorouracil*	Low: bolus Minimal: CIV
Gemcitabine	Low
Idarubicin	Moderate
Ifosfamide	Moderate
Interferon alfa-2b	Minimal
Ipilimumab	Minimal
Irinotecan	Moderate
Irinotecan Liposomal	Moderate
Melphalan	Moderate
Methotrexate*	Moderate: $\geq 250 \text{ mg/m}^2$ Low: > 30 and $< 250 \text{ mg/m}^2$ Minimal: $\leq 30 \text{ mg/m}^2$
Mitomycin	Low
Mitoxantrone	Low
Nab-Paclitaxel	Low
Nelarabine	Minimal
Nivolumab	Minimal
Obinutuzumab	Minimal
Ofatumumab	Minimal
Oxaliplatin	Moderate
Paclitaxel	Low
Panitumumab	Minimal

The agents listed in this table are based on the CCO Drug Formulary as at February 2019, and may not be inclusive of all agents. Refer to the Drug Formulary website for the most up-to-date information on individual agents, to find the latest CCO Antiemetic Recommendations, and for more information on emetic risk of multi-drug combinations. The contents of this document are not a substitute for the advice of a qualified health professional. Any person consulting it is expected to use independent qualified clinical judgment and skills, or seek out the advice of a qualified health professional before applying any information contained herein. Cancer Care Ontario does not make any representation or warranty as to the accuracy, reliability, completeness or fitness for a particular purpose of the information in this document, and disclaims all liability for the use of this document, and for any claims, actions, demands or suits that arise from such use.

Drug Name	Emetic Risk Category
Pegaspargase	Minimal
Pembrolizumab	Minimal
Pemetrexed	Low
Pertuzumab	Minimal
Porfimer	Minimal
Pralatrexate*	Low
Raltitrexed	Low
Ramucirumab*	Minimal
Rituximab	Minimal
Romidepsin	Low
Siltuximab	Minimal
Streptozocin	High
Temsirolimus	Minimal
Teniposide	Low
Topotecan	Low
Trabectedin	Moderate
Trastuzumab	Minimal
Trastuzumab emtansine	Minimal
Vinblastine	Minimal
Vincristine	Minimal
Vinorelbine	Minimal

* Denotes a change to emetic risk category from the 2013 Antiemetic Report
 CIV = Continuous Intravenous Infusion